Related Experiment Videos

Cytokines as potential therapeutic targets for inflammatory skin diseases

Robert P Numerof1, Charles A Dinarello, Khusru Asadullah

  • 1RBA Dermatology USA, Berlex Biosciences, 2600 Hilltop Drive, PO Box 4099, Richmond, CA 94804-0099, USA. robert_numerof@berlex.com

European Cytokine Network
|June 9, 2005
PubMed

Insights

Cytokines drive inflammatory skin diseases. New therapies targeting specific cytokines like IFN-gamma and IL-18, alongside their signaling pathways, show promise for treating conditions such as psoriasis.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Pro-inflammatory cytokines are key in inflammatory skin disease pathology.
  • Targeting cytokines is a growing area of therapeutic research.
  • Anti-TNF therapies are effective for psoriasis, prompting investigation into other cytokines.

Purpose of the Study:

  • To review recent findings on cytokines as therapeutic targets for inflammatory skin diseases.
  • To highlight emerging cytokine-directed therapies and pathway strategies.

Main Methods:

  • Summary of key findings from a recent workshop.
  • Review of current research on cytokine roles and therapeutic targeting.

Main Results:

  • Established efficacy of anti-TNF therapies for psoriasis.
  • Ongoing clinical investigations for therapies targeting IFN-gamma, IL-12p40, and IL-18.
  • Development of strategies targeting cytokine signaling pathways.

Conclusions:

  • Cytokines represent crucial therapeutic targets for inflammatory skin conditions.
  • Diverse cytokine-targeting strategies are under active investigation and development.

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...